Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07170917 · ClinicalTrials.gov registry record · Phase 2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 208
- Enrollment target
- 20
- Study locations
NCT07170917 is a Phase 2 study of Hidradenitis Suppurativa that is actively recruiting participants, run by Sanofi. The registered enrollment target is 208 participants, below the 594-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT07170917, a Phase 2 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 208 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa. The purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe HS. Study details include: The study duration (per participant) will be up to approximately 60 weeks for participants not transitioning into the long-term extension (LTE) study and will be up to approximately 52 weeks for participants transitioning into the LTE study. The randomized treatment duration will be up to approximately 48 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Brivekimig
Study Locations (20)
Reg Metropolitana de Santiago
- Investigational Site Number: 1520003 - Santiago
- Investigational Site Number: 1520002 - Santiago
- Investigational Site Number: 1520001 - Santiago
- Investigational Site Number: 1520005 - Santiago
Florida
- FXM Clinical Research - Miami- Site Number : 8400017 - Miami
- FXM Clinical Research Miramar, LLC - Site Number: 8400004 - Miramar
Georgia
- Advanced Medical Research - Atlanta- Site Number : 8400011 - Atlanta
- Georgia Skin & Cancer Clinic- Site Number : 8400009 - Savannah
Ontario
- Lima's Excellence in Allergy and Dermatology Research (LEADER) Inc. - Hamilton
- Investigational Site Number : 1240009 - Toronto
California
- Northridge Clinical Trials - Northridge- Site Number : 8400005 - Northridge
Louisiana
- Louisiana Dermatology Associates- Site Number : 8400006 - Baton Rouge
Rhode Island
- Clinical Partners- Site Number : 8400002 - Johnston
South Carolina
- AMR Clinical South Strand, South Carolina- Site Number : 8400018 - Myrtle Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2028-04-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07170917
The ClinicalTrials.gov registry entry for NCT07170917 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 594-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (65% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07170917 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Reg Metropolitana de Santiago, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07170917 about?
NCT07170917 is a clinical study titled "Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa". This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa. The purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging ...
What is the current status of trial NCT07170917?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2025-11-06. Estimated completion is 2028-04-27.
What conditions does trial NCT07170917 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT07170917?
The interventions under investigation include: Placebo (DRUG), Brivekimig (DRUG).
Who is sponsoring clinical trial NCT07170917?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07170917 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Louisiana, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.